Solventum vs Becton Dickinson

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (76 vs 79)
Solventum logo

Solventum

LeaderHealthcare Tech

Medical Technology

Solventum (SOLV) reported ~$8.2B revenue in FY2024. Medical technology company spun off from 3M in 2024, providing wound care, oral care, healthcare IT, and purification products. HQ: Maplewood, MN.

AI VisibilityBeta
Overall Score
B76
Category Rank
#72 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
78
Gemini
71

About

Solventum Corporation is a global medical technology company spun off from 3M Company in April 2024, combining 3M's Health Care segment into an independent publicly traded entity. The company operates four business segments: MedSurg (wound management, surgical solutions), Dental Solutions (3M/Solventum brand dental products), Health Information Systems (clinical documentation and coding software), and Purification & Filtration (membrane filtration for pharmaceuticals and food/beverage). The spinoff created a focused MedTech company with $8+ billion in revenue and operations in over 70 countries.

Full profile
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
B79
Category Rank
#25 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
76
Perplexity
82
Gemini
84

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile

AI Visibility Head-to-Head

76
Overall Score
79
#72
Category Rank
#25
81
AI Consensus
77
stable
Trend
stable
77
ChatGPT
76
78
Perplexity
82
71
Gemini
84
73
Claude
84
72
Grok
77

Key Details

Category
Medical Technology
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Solventum
Medical Technology

Integrations

Only Solventum
Only Becton Dickinson
Solventum is classified as company. Becton Dickinson is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.